110 related articles for article (PubMed ID: 37300277)
1. Aberrant epigenetic regulation of FZD3 by TET2 is involved in ovarian cancer cell resistance to cisplatin.
Zhu L; Zhou Q
J Chemother; 2024 Apr; 36(2):143-155. PubMed ID: 37300277
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic editing of
He W; Zhu H; Zhang S; Shu G; Lei H; Wang M; Yin G; Ni X; Wu Q
Epigenetics; 2024 Dec; 19(1):2357518. PubMed ID: 38796857
[TBL] [Abstract][Full Text] [Related]
3. Circ_0078607 increases platinum drug sensitivity via miR-196b-5p/GAS7 axis in ovarian cancer.
Dai C; Dai SY; Gao Y; Yan T; Zhou QY; Liu SJ; Liu X; Deng DN; Wang DH; Qin QF; Zi D
Epigenetics; 2023 Dec; 18(1):2175565. PubMed ID: 36908025
[TBL] [Abstract][Full Text] [Related]
4. Silencing of miR-1246 Induces Cell Cycle Arrest and Apoptosis in Cisplatin-Resistant Ovarian Cancer Cells by Promoting ZNF23 Transcription.
Cai L; Zhang Q; Du L; Zheng F
Cytogenet Genome Res; 2021; 161(10-11):488-500. PubMed ID: 34923485
[TBL] [Abstract][Full Text] [Related]
5. Downregulated expression levels of USP46 promote the resistance of ovarian cancer to cisplatin and are regulated by PUM2.
Xu L; Zhang B; Li W
Mol Med Rep; 2021 Apr; 23(4):. PubMed ID: 33576437
[TBL] [Abstract][Full Text] [Related]
6.
Yang H; Zhang X; Zhu L; Yang Y; Yin X
DNA Cell Biol; 2021 Jun; 40(6):821-832. PubMed ID: 34030482
[TBL] [Abstract][Full Text] [Related]
7. Circ_0067934 reduces JNK phosphorylation through a microRNA-545-3p/PPA1 axis to enhance tumorigenesis and cisplatin resistance in ovarian cancer.
Yin Y; Li J; Rong J; Zhang B; Wang X; Han H
Immunopharmacol Immunotoxicol; 2022 Apr; 44(2):261-274. PubMed ID: 35179434
[TBL] [Abstract][Full Text] [Related]
8. Toosendanin reduces cisplatin resistance in ovarian cancer through modulating the miR-195/ERK/β-catenin pathway.
Wang G; Li L; Li Y; Zhang LH
Phytomedicine; 2023 Jan; 109():154571. PubMed ID: 36610147
[TBL] [Abstract][Full Text] [Related]
9. Circ_0007841 knockdown confers cisplatin sensitivity to ovarian cancer cells by down-regulation of NFIB expression in a miR-532-5p-dependent manner.
Gao Y; Huang Y
J Chemother; 2023 Apr; 35(2):117-130. PubMed ID: 35380509
[TBL] [Abstract][Full Text] [Related]
10. Knockdown of lncRNA ACTA2-AS1 reverses cisplatin resistance of ovarian cancer cells via inhibition of miR-378a-3p-regulated Wnt5a.
Lin C; Zheng M; Yang Y; Chen Y; Zhang X; Zhu L; Zhang H
Bioengineered; 2022 Apr; 13(4):9829-9838. PubMed ID: 35412951
[TBL] [Abstract][Full Text] [Related]
11. Hedgehog-Gli2 Signaling Promotes Chemoresistance in Ovarian Cancer Cells by Regulating MDR1.
Wang Q; Wei X; Hu L; Zhuang L; Zhang H; Chen Q
Front Oncol; 2021; 11():794959. PubMed ID: 35059317
[TBL] [Abstract][Full Text] [Related]
12. Knockdown of circ-PIP5K1A overcomes resistance to cisplatin in ovarian cancer by miR-942-5p/NFIB axis.
Sheng H; Wang X
Anticancer Drugs; 2023 Feb; 34(2):214-226. PubMed ID: 36730637
[TBL] [Abstract][Full Text] [Related]
13. Lentivirus-Mediated RNAi silencing targeting ERCC1 reverses cisplatin resistance in cisplatin-resistant ovarian carcinoma cell line.
Du P; Zhang X; Liu H; Chen L
DNA Cell Biol; 2015 Jul; 34(7):497-502. PubMed ID: 25941922
[TBL] [Abstract][Full Text] [Related]
14. Circ_0026123 promotes cisplatin resistance and progression of ovarian cancer by upregulating RAB1A through sequestering miR-543.
Wei L; He W; Zhao H; Zhao P
Anticancer Drugs; 2022 Nov; 33(10):1069-1080. PubMed ID: 36255068
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic microRNA-181d binding to OGT contributes to resistance of ovarian cancer cells to cisplatin.
Huang W; Chen L; Zhu K; Wang D
Cell Death Discov; 2021 Dec; 7(1):379. PubMed ID: 34876558
[TBL] [Abstract][Full Text] [Related]
16. Long non-coding RNA CTSLP8 mediates ovarian cancer progression and chemotherapy resistance by modulating cellular glycolysis and regulating c-Myc expression through PKM2.
Li X; Zhang Y; Wang X; Lin F; Cheng X; Wang Z; Wang X
Cell Biol Toxicol; 2022 Dec; 38(6):1027-1045. PubMed ID: 34510316
[TBL] [Abstract][Full Text] [Related]
17. Long non-coding RNA GAS5 inhibits DDP-resistance and tumor progression of epithelial ovarian cancer via GAS5-E2F4-PARP1-MAPK axis.
Long X; Song K; Hu H; Tian Q; Wang W; Dong Q; Yin X; Di W
J Exp Clin Cancer Res; 2019 Aug; 38(1):345. PubMed ID: 31391118
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of microRNA-195-5p reduces cisplatin resistance and angiogenesis in ovarian cancer by inhibiting the PSAT1-dependent GSK3β/β-catenin signaling pathway.
Dai J; Wei R; Zhang P; Kong B
J Transl Med; 2019 Jun; 17(1):190. PubMed ID: 31171023
[TBL] [Abstract][Full Text] [Related]
19. Stanniocalcin 1 promotes metastasis, lipid metabolism and cisplatin chemoresistance via the FOXC2/ITGB6 signaling axis in ovarian cancer.
Lin F; Li X; Wang X; Sun H; Wang Z; Wang X
J Exp Clin Cancer Res; 2022 Apr; 41(1):129. PubMed ID: 35392966
[TBL] [Abstract][Full Text] [Related]
20. Exosomal miR-21-5p derived from cisplatin-resistant SKOV3 ovarian cancer cells promotes glycolysis and inhibits chemosensitivity of its progenitor SKOV3 cells by targeting PDHA1.
Zhuang L; Zhang B; Liu X; Lin L; Wang L; Hong Z; Chen J
Cell Biol Int; 2021 Oct; 45(10):2140-2149. PubMed ID: 34288231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
